IDEXX Laboratories, Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
IDEXX Laboratories reported robust Q3 2025 results with a 13% rise in revenue, bolstered by strong performance in their Companion Animal Group (CAG) business despite some headwinds from clinical visit declines.
Key takeaways
- Revenue increased to $1.080 billion, a 13% year-over-year jump, with organic growth at 12%.
- CAG Diagnostics recurring revenues grew 10% organically, driven by a significant rise in premium instrument placements, including over 1,750 InVue Dx analyzers resulting in 71% growth in instrument revenues.
- Updated full-year guidance reflects increased revenue expectations of $4.270-$4.300 billion and EPS outlook raised to $12.81-$13.01, indicating strong operational momentum despite macro challenges.